Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements
In tackling reverse payments, should a different policy tact might be called for; one that shifts emphasis from determining whether or not reverse payments should be per se illegal to working with the incentives that firms already face.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
When requesting a correction, please mention this item's handle: RePEc:cpi:cpijrn:5.2.2009:i=5339. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Lindsay McSweeney)
If references are entirely missing, you can add them using this form.